Summary of COVID-19 medicines guidance: Policy, Commissioning and Managerial

Laura Kearney, Regional Principal Medicines Information Pharmacist, Midlands and East Medicines Advice Service (Midlands site) & UK Drugs in Lactation Advisory ServicePublished Last updated See all updates

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to Policy and Commissioning during coronavirus pandemic.

Our advice is constantly reviewed as the pandemic situation evolves.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

 

NHS England/NHS Improvement: Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and over) version 3 

Last updated 15 June 2021

  • This policy sets out the interim clinical commissioning position for the use of remdesivir for patients with COVID-19.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) guidance on coronavirus

Last updated 16 September 2021

Summary

  • Repository of guidance and information for industry, healthcare professionals and patients covering the coronavirus (COVID-19) pandemic.
  • Includes latest clinical trial and vaccination information.
  • Includes guidance on relevant medicine and medical devices.

 

HM Government: COVID-19: guidance for health professionals

Last updated 22 October 2021

  • This is a repository of a number of guidelines regarding the assessment and management of suspected and confirmed UK cases.
  • It includes general guidance as well as guidance on infection prevention and control, adult social care, sampling and laboratory diagnostics, and surveillance reports.

 

HM Government: Covid-19: investigation and initial clinical management of possible cases

Last updated 14 December 2020

  • This generalised guidance is for clinicians clinically assessing potential COVID-19 cases.
  • It describes the definition of a COVID-19 infection, when testing should be considered, and actions to take if a case requires admission to hospital.

 

HM Government: Guidance for people previously considered clinically extremely vulnerable from COVID-19

Last updated 24 December 2021

  • The shielding programme ended in England on 15 September 2021.
  • Guidance is provided about how those who were previously defined as extremely clinically vulnerable can now minimise risk.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) Coronavirus Yellow Card reporting site

Summary

  • Healthcare professionals, patients and carers can report all suspected adverse drug reactions associated with any medicines used in patients with confirmed or suspected COVID-19.
  • This includes medicines to manage long term or pre-existing conditions and medicines being used off-label and in clinical trials.
  • The site has been developed as part of the MHRA’s work to protect the public through enhanced COVID-19 vigilance and in preparation for large-scale use of potential new or repurposed medicines, medical devices, diagnostic tests and future vaccines.
  • Reporting for incidents in clinical trials should also still be reported in line with trial protocols.

Change history

  1. HM Government/PHE: Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19 removed. Replaced with Guidance for people previously considered clinically extremely vulnerable from COVID-19.
  2. Editorial amendments
  3. NHSE/I: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic (removed: guideline no longer available)
  1. Editorial amendments
  2. NHSE/: Interim Clinical Commissioning Policy for remdesivir (updated to version 3)
  1. HM Government: COVID-19: guidance for health professionals (link updated)
  1. NHSE/I: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic (link updated)
  2. NHSE/I: Community pharmacy in the context of coronavirus (COVID-19) (removed: guideline no longer available)
  3. NHSE/I: Clinical Management of persons admitted to hospital with suspected COVID-19 infection (removed: guideline no longer available)
  4. Editorial amendments
  5. HM Government: COVID-19: investigation and initial clinical management of possible cases (new guideline added)
  1. Published